Lyka Labs Reports Q1 FY27 Unaudited Financial Results; Standalone Net Profit Jumps 159%
Lyka Labs Limited announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported significant increases across key revenue and profitability metrics, driven by robust performances in both domestic and international markets.The management confirmed that the Board of Directors had approved these Q1 FY27 financial results.
Key highlights from the quarter include:
- Net Total Income: Standalone Net Total Income saw a rise of 42.67%, reaching Rs. 4272.79 Lacs, while Consolidated Net Total Income also increased by 26.95% at Rs. 4272.79 Lacs.
- Revenue Growth: Domestic Revenue grew by 15.91%, totaling Rs. 2652.11 Lacs. Meanwhile, Export Revenue demonstrated strong growth of 68.03%, amounting to Rs. 1483.42 Lacs.
The company’s profitability ratios reflected fluctuations compared to the previous fiscal year's first quarter (Q1 FY26). Standalone EBITDA margin stood at 11.84% in Q1 FY27, down from 14.16% in Q1 FY26. Similarly, the Consolidated EBITDA margin was recorded at 11.74% for Q1 FY27, compared to 13.07% in Q1 FY26.
Net Profit saw substantial increases across the board divisions. Standalone Net Profit rose by a significant 159.04%, recording Rs. 210.01 Lacs. The Consolidated Net Profit increased by 105.44%, reaching Rs. 204.66 Lacs.
Financial Performance Metrics
The Q1 FY27 results show varied performance across the standalone and consolidated segments when compared to Q1 FY26, particularly in terms of operating income and profit after tax.A detailed comparison of the Standalone Q1 FY27 against Q1 FY26 is provided below:
| Particulars | Q1 FY27 (Rs.) | Q1 FY26 (Rs.) | Growth (%) |
|---|---|---|---|
| Revenue from Operations | 4230.94 | 2917.64 | 45.01 |
| EBITDA | 501.12 | 413.06 | 21.32 |
| Other Income | 41.85 | 77.34 | -45.89 |
| Finance Cost | 100.82 | 85.14 | 18.42 |
| Depreciation and Amortisation | 200.96 | 211.18 | -4.84 |
| Net Profit after tax | 199.33 | 116.74 | 70.75 |
The Consolidated Q1 FY27 performance mirrored strong operational growth:
| Particulars | Q1 FY27 (Rs. in lacs) | Q1 FY26 (Rs. in lacs) | Growth (%) |
|---|---|---|---|
| Revenue from Operations | 4230.94 | 3302.54 | 28.11 |
| EBITDA | 496.57 | 431.73 | 15.02 |
| Other Income | 41.85 | 63.09 | -33.67 |
| Finance Cost | 100.81 | 85.38 | 18.07 |
| Depreciation and amortisation | 200.96 | 211.18 | -4.84 |
| Net Profit after tax | 194.80 | 135.17 | 44.11 |
Q1 FY27 Revenue Breakdown
The revenue streams were detailed across domestic and export segments, showing the following breakdown:| Particulars | Q1 FY27 (Rs.) | Q1 FY26 (Rs.) | Growth (%) |
|---|---|---|---|
| Domestic Segment | |||
| Branded Formulation | 737.67 | 454.58 | 62.27 |
| Branded Veterinary | 587.35 | 296.90 | 97.83 |
| P2P | 1,327.09 | 1,536.69 | -13.64 |
| Total Domestic Sales | 2,652.11 | 2,288.17 | 15.91 |
| Export Segment | |||
| Branded Formulation | 1,483.42 | 882.85 | 68.03 |
| Consolidated Revenue from Operations | 4,230.94 | 3,302.54 |
Lyka Labs Limited operates in the field of Manufacturing and Marketing of Finished Formulations for Human and Animal Healthcare across various therapeutic segments.
LYKALABS Stock Price Movement
Shares of LYKALABS are edging higher to ₹67.2 as of 12:53 PM today, climbing by 0.69% in live trading. The equity maintains positive momentum throughout the session despite volatility across the micro-market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.